Financial Performance - The company's operating revenue for the first half of 2023 was ¥10,024,249,628.07, representing a 7.32% increase compared to ¥9,340,896,235.85 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was ¥189,013,659.46, up 12.00% from ¥168,764,960.24 year-on-year[18]. - The net cash flow from operating activities surged to ¥421,976,736.58, a significant increase of 2,188.99% compared to ¥18,435,029.72 in the previous year[18]. - The basic earnings per share rose to ¥0.49, reflecting a 13.95% increase from ¥0.43 in the same period last year[18]. - Total assets at the end of the reporting period were ¥11,482,301,358.41, down 2.56% from ¥11,783,796,364.82 at the end of the previous year[18]. - The net assets attributable to shareholders increased by 2.72% to ¥2,794,777,812.97 from ¥2,720,812,852.98 at the end of the previous year[18]. - The company reported a significant increase in net profit from recurring operations, which was ¥180,266,833.47, an 8.24% increase from ¥166,546,887.92 in the previous year[18]. - The weighted average return on net assets was 6.71%, slightly up from 6.55% in the same period last year[18]. Dividend and Shareholder Returns - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[4]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period, nor to increase share capital from capital reserves[77]. Market Position and Competition - The company ranked 15th among the top 100 pharmaceutical wholesale enterprises in China, maintaining its position as the largest pharmaceutical distribution company in Fujian Province for 13 consecutive years[27]. - The retail module of the company entered the top 100 in the "2022-2023 China Pharmacy Value List," ranking 87th[27]. - The company faces a risk of goodwill impairment due to its expansion strategy; if acquired companies do not meet performance expectations, it could significantly affect overall financial performance[72]. - The company is focusing on differentiated business expansion strategies in the medical device procurement sector, adapting to market demand changes[35]. - The company is actively exploring new retail channels and improving its O2O and B2C operational capabilities[36]. Operational Efficiency and Cost Management - The cost of goods sold increased by 7.68% to ¥9,281,898,532.66 from ¥8,620,234,602.90, indicating a rise in operational expenses[48]. - The company's pharmaceutical distribution business grew by 6.05% during the reporting period[35]. - The company's inventory decreased by 1.70% to ¥2,288,408,504.08 from ¥2,548,589,433.26, indicating improved inventory management[55]. - The company has implemented a new "dual control" management system to enhance capital efficiency and risk management[35]. - The company is enhancing its supply chain management capabilities to meet the needs of upstream suppliers and downstream customers[42]. Research and Development - Research and development expenses rose by 38.41% to ¥1,938,212.92, up from ¥1,400,296.54, reflecting increased investment in AI projects[49]. - The company is actively investing in the traditional Chinese medicine (TCM) sector, expanding production capacity and developing a modern TCM production project[33]. - The company is accelerating the construction of modern Chinese medicine production projects and enhancing R&D investment to expand product variety and production capacity[37]. - The company has allocated 8,000 million for research and development in 2023, emphasizing innovation in medical devices[102]. - Research and development expenses increased by 12% in the first half of 2023, totaling 914.36 million, reflecting the company's commitment to innovation[103]. Legal and Regulatory Matters - The company has not faced any significant litigation or arbitration matters during the reporting period[88]. - The company has ongoing litigation involving 34 cases with a total amount of 77.72 million yuan, of which 25 cases have been resolved in favor of the company, recovering 1.67 million yuan[90]. - The company has initiated litigation against Chengdu Hechuang for a total compensation claim of CNY 23.1 million, with a separate claim of CNY 20 million for damages[125]. Future Outlook and Guidance - The company has provided a positive outlook for the remainder of 2023, projecting a revenue growth of approximately 15%[104]. - The company has set a performance guidance of 4,000 million in revenue for the full year 2023, indicating strong confidence in market demand[104]. - Future guidance for 2023 indicates expected revenue growth of 8% to 10%, with projected total revenue between 3,000 million and 3,300 million[103]. - The company plans to expand its market presence by entering three new regions by the end of 2023, aiming for a 10% market share in these areas[104]. Corporate Governance and Compliance - The financial statements were approved by the board of directors on August 4, 2023, indicating a commitment to transparency and regulatory compliance[183]. - The company has established a corporate governance structure that includes a shareholders' meeting, board of directors, and supervisory board[181]. - The company adheres to the accounting standards set forth by the Chinese regulatory authorities, ensuring the accuracy and completeness of its financial reporting[189].

证券代码：002788 证券简称：鹭燕医药 鹭燕医药股份有限公司 投资者关系活动记录表 编号：2023-009 √特定对象调研 □分析师会议 投资者关系 活动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 √现场参观 □其他（请文字说明其他活动内容） 参与单位名称 及人员姓名 国信证券 时间 2023 年 6 月 21 日 9:30-12:00 地点 鹭燕医药会议室 上市公司 接待人员姓名 董事会秘书叶泉青、证券事务代表阮翠婷 一、介绍公司基本概况、业务布局。 二、沟通交流环节 1、公司分销模块现阶段的布局情况及未来发展的规划？ 答：公司现阶段的业务模式以纯销为主，于2009年实现了对 福建省二级以上医疗机构100%覆盖；经过多年深耕以县级医院为 龙头的农村三级医疗卫生服务网，销售终端已覆盖各级医院、卫 生站、诊所及终端药店，并完成了电子商务平台销售渠道的搭建。 投资者关系活 动主要内容介 绍 此外，公司通过并购扩张，在四川、江西、海南三省布局医 药分销业务，在四川、江西、海南三省二级以上公立医疗机构的 覆盖率超95%。未来公司将继续做好"三个能力"建设，即药事 服务能力、准入能力、终端营销能力等， ...

证券代码：002788 证券简称：鹭燕医药 鹭燕医药股份有限公司 投资者关系活动记录表 编号：2023-008 √特定对象调研 □分析师会议 投资者关系 活动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 √现场参观 □其他（请文字说明其他活动内容） 兴业证券、相聚资本、安信基金、富荣基金、长城基金、深圳私 参与单位名称 及人员姓名 享、嘉实基金、申万菱信基金、华夏久盈资产、东方红、大成基 金、诺德基金、合众资产、广发资管等 14 家机构。 时间 2023 年 6 月 15 日 10:00-12:00 地点 会议室 上市公司 接待人员姓名 董事会秘书叶泉青、证券事务代表阮翠婷 一、介绍公司基本概况、业务布局。 二、沟通交流环节 1、亳州中药饮片厂年产值及未来规划？目前建设进度如 何？ 答：中药饮片的市场，未来会同西药的趋势一样。集采的品 种和规模越来越大。刚结束的中药饮片省际联盟集采就是这个趋 投资者关系活 动主要内容介 绍 势的反映。随着中药饮片的监管越来越严、市场越来越规范，市 场中原有的小生产企业生存压力变大，有规模效应、管理规范的 生产企业将获得更大的市场份额。 目前公司下属二家中药饮片生产 ...

Business Overview and Revenue Distribution - In 2022, the company achieved approximately 14 billion yuan in revenue in Fujian Province, 3 billion yuan in Sichuan Province, 2 billion yuan in Jiangxi Province, and 500 million yuan in Hainan Province [2] - Fujian Province accounts for the majority of the company's revenue, but there is still room for growth in various cities within the province [2] - The company's market share outside Fujian Province is relatively small, but it is expected to grow significantly due to ongoing healthcare reforms and centralized procurement policies [2] Profitability and Market Trends - The gross profit margin in Fujian Province is 7%, while it is 9% outside Fujian Province, primarily due to stricter healthcare reforms and lower capital occupation in Fujian [3] - The company expects the market concentration in the pharmaceutical distribution industry to increase significantly as healthcare reforms and centralized procurement policies are implemented nationwide [3] - The company believes that the core goal of healthcare reform is to eliminate unreasonable factors in the pharmaceutical distribution process, which will lead to shorter distribution channels and reduced costs [3] Competitive Advantages and Future Strategies - The company has achieved full coverage of medical institutions in Fujian Province and has core competitiveness in responding to market demands and providing customer service [3] - The company plans to focus on building three key capabilities: pharmaceutical service capability, market access capability, and terminal marketing capability [3] - The company's retail pharmacy business will focus on refined management and operational efficiency, with no strict targets for store expansion but potential mergers and acquisitions to accelerate growth [4] - The company has a competitive advantage in the Fujian market due to its brand effect and integrated wholesale-retail model [4] Expansion and Innovation - The company has successfully expanded into Sichuan, Jiangxi, and Hainan through mergers and acquisitions, with the main challenge being the long accounts receivable period outside Fujian Province [5] - The company plans to deepen its market penetration in these regions and focus on strengthening its retail and innovative business operations [5] - The company is developing AI-based medical devices, including dynamic ECG recorders, fetal heart monitoring systems, and AI-assisted cardiac ultrasound image diagnosis systems, which are currently in the commercialization phase [4] Industrial and Medical Equipment Business - The company's industrial segment focuses on the production and sales of traditional Chinese medicine (TCM) decoction pieces, with plans to potentially expand into TCM formula granules in the future [4] - The company expects significant growth in its industrial segment as it expands its service areas and increases production capacity [4] - The medical equipment distribution sector is expected to follow the same trend as pharmaceuticals, with further deepening of centralized procurement and increased market concentration [4]

证券代码：002788 证券简称：鹭燕医药 鹭燕医药股份有限公司 投资者关系活动记录表 编号：2023-006 √特定对象调研 □分析师会议 投资者关系 活动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（请文字说明其他活动内容） 参与单位名称 及人员姓名 兴业证券王声亮、涂磊 时间 2023 年 6 月 6 日 15:00-16:00 地点 鹭燕医药会议室 上市公司 接待人员姓名 董事会秘书叶泉青、证券事务代表阮翠婷 一、介绍公司基本概况、业务布局。 二、沟通交流环节 1、医药流通行业中，国企、民企各有什么竞争优势，未来 的行业格局如何？ 答：国企的优势主要体现在资源、政策扶持方面。而民企机 制灵活，对市场反馈迅速、精细化管理等方面更强。国企和民企 能够对客户的需求提供差异化服务。对于医药流通领域来说，具 投资者关系活 动主要内容介 绍 有全国网络优势的巨头与区域的龙头并存的格局仍然将持续存 在。 2、公司在四川、江西省的市场占有率情况？ 答：公司在四川、江西省目前已基本完成分销网络布局，后 续将持续深耕市场，提升市场占有率。 3、应收账款回款情况是否有变化？四川、江西应收账款 ...

投资者关系活动类 别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 活动参与人员 线上参与 2023 年厦门辖区上市公司投资者网上集体接 待日的投资者 时间 2023 年 05 月 12 日（星期五）下午 14:30-16:15 地点 全景网"投资者关系互动平台"（https://ir.p5w.net） 形式 网络远程交流 上市公司接待人员 姓名 董事长兼总经理：吴金祥先生 董事、副总经理兼财务总监：杨聪金女士 独立董事：叶少琴女士 董事会办公室主任兼董事会秘书：叶泉青先生 交流内容及具体问 答记录 1、请问董事长，合作研发的心电仪市场推广成效如何？ 预计今年的利润贡献率是多少？ 答：公司根据市场情况制定业务发展策略，推动业务增 长，谢谢。 2、请问董事长，今年对鹭燕医药的市值管理有什么新举 措？ 答：公司一方面将持续提高公司的核心竞争力，提高运 营效率，扩大市场份额，实现业绩持续增长；另一方面， 公司将严守合规底线，规范运作，不断提高内部控制水 平，完善法人治理结构；通过不断提升公司价值实现公 司市值的增长。 | | 3、请 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 4,841,503,352.57, representing a 4.40% increase compared to CNY 4,637,268,373.59 in the same period last year[5] - Net profit attributable to shareholders was CNY 79,861,688.20, an increase of 11.37% from CNY 71,706,561.12 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 4,841,503,352.57, an increase of 4.4% compared to CNY 4,637,268,373.59 in Q1 2022[23] - Net profit for Q1 2023 reached CNY 78,600,499.56, compared to CNY 71,333,431.99 in Q1 2022, representing a growth of 10.1%[24] - The net profit attributable to the parent company was CNY 79,861,688.20, an increase from CNY 71,706,561.12 in the previous year, marking a rise of 11.5%[24] - Basic earnings per share for Q1 2023 were CNY 0.21, up from CNY 0.18 in Q1 2022[24] Cash Flow - The net cash flow from operating activities increased by 127.21%, reaching CNY 113,401,415.76, compared to a negative cash flow of CNY -416,697,576.75 in the previous year[5] - Cash inflow from operating activities totaled ¥5,408,013,910.72, compared to ¥4,650,047,143.44 in the prior period, reflecting a year-over-year increase of approximately 16.3%[27] - Cash outflow from operating activities was ¥5,294,612,494.96, up from ¥5,066,744,720.19, indicating a rise of about 4.5%[27] - The ending balance of cash and cash equivalents was ¥341,124,938.55, up from ¥255,336,795.43, marking an increase of approximately 33.5%[28] - The company paid ¥68,752,595.94 in dividends and interest, compared to ¥44,527,421.71 in the previous period, reflecting a rise of about 54.3%[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,349,841,193.41, a decrease of 3.68% from CNY 11,783,796,364.82 at the end of the previous year[5] - Total liabilities decreased to CNY 8,488,723,106.98 from CNY 8,993,147,283.00 year-on-year[21] - The company's total equity increased to CNY 2,861,118,086.43, compared to CNY 2,790,649,081.82 in the previous year[21] - Total current assets decreased from 9.75 billion yuan to 9.29 billion yuan, a decline of approximately 4.7%[17] Accounts Receivable and Inventory - Accounts receivable increased by 604.75% to CNY 3,347,600.00, primarily due to received bills not being endorsed or discounted[9] - Accounts receivable increased slightly from 5.84 billion yuan to 5.85 billion yuan, indicating a marginal growth of 0.03%[17] - Inventory decreased from 2.55 billion yuan to 2.38 billion yuan, representing a reduction of about 6.7%[17] Legal Matters - The company has initiated legal proceedings to recover 39.69 million yuan in damages from Guizhou Mingrun Construction Engineering Co., Ltd. and Chengdu Hechuang Ruida Enterprise Management Co., Ltd.[16] - The company has successfully enforced the collection of 8 million yuan in breach of contract damages from Guizhou Mingrun Construction Engineering Co., Ltd.[15] - Chengdu Hechuang has filed a new lawsuit seeking compensation of 31.63 million yuan plus interest from the aforementioned companies[16] Research and Development - Research and development expenses for Q1 2023 were CNY 769,300.60, up from CNY 602,864.18 in Q1 2022, indicating a focus on innovation[23] Other Financial Metrics - The company reported a decrease in other comprehensive income, with a net amount of CNY -441,714.34 for Q1 2023 compared to CNY -279,198.76 in Q1 2022[24] - The company reported a significant increase in other current assets, which rose by 67.05% to CNY 66,615,100.00, attributed to an increase in input tax credits[9] - The balance of prepayments decreased by 37.71% to CNY 391,556,800.00, mainly due to the settlement of a large amount of prepaid epidemic prevention material payments[9] - The company has actively explored new financing tools such as supply chain financing and factoring, contributing to improved cash flow management[9]

Financial Performance - The company's operating revenue for 2022 was ¥19,462,501,277.53, representing a 10.93% increase compared to ¥17,545,397,267.57 in 2021[18]. - The net profit attributable to shareholders for 2022 was ¥345,155,498.99, up 12.84% from ¥305,870,612.74 in 2021[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥340,489,265.34, an 18.34% increase from ¥287,727,554.44 in 2021[18]. - The net cash flow from operating activities improved significantly to ¥232,186,445.57, a 162.41% increase from a negative cash flow of ¥372,020,787.97 in 2021[18]. - The total assets at the end of 2022 were ¥11,783,796,364.82, reflecting a 17.92% increase from ¥9,992,695,467.80 at the end of 2021[18]. - The net assets attributable to shareholders increased by 9.20% to ¥2,720,812,852.98 from ¥2,491,664,451.63 in 2021[18]. - The basic earnings per share for 2022 were ¥0.89, up 12.66% from ¥0.79 in 2021[18]. - The weighted average return on equity for 2022 was 13.01%, an increase from 11.82% in 2021[18]. Revenue Breakdown - The pharmaceutical wholesale segment generated ¥18,191,799,102.85, accounting for 93.47% of total revenue, with a year-on-year growth of 10.28%[54]. - The retail pharmaceutical segment saw revenue of ¥847,422,246.95, reflecting a significant increase of 17.86% from the previous year[54]. - The company’s pharmaceutical distribution business grew by 10.28% despite the adverse impact of centralized procurement policies[40]. - Medical device sales revenue increased by 16.64% during the reporting period[40]. - Retail business sales revenue saw a year-on-year growth of 17.86%[41]. - The company achieved total operating revenue of CNY 1,946,250.13 million, a year-on-year increase of 10.93%[38]. Market Presence and Expansion - The company ranked 15th among the top 100 pharmaceutical wholesale enterprises in China in 2021, maintaining its position as the largest pharmaceutical distribution company in Fujian Province[30]. - The company has achieved 100% coverage of secondary and higher medical institutions in Fujian Province since 2009, enhancing its market presence[34]. - The company is actively expanding its market presence in Sichuan, Jiangxi, and Hainan provinces through acquisitions, strengthening its competitive edge[34]. - The company has established a distribution and logistics network covering all public medical institutions in Fujian Province, with over 95% coverage in secondary hospitals in Sichuan, Jiangxi, and Hainan provinces[45]. - The company is committed to expanding its market presence beyond Fujian province, aiming for sustainable growth through both internal and external strategies[90]. Research and Development - Research and development expenses rose to ¥4,146,496.57, marking a significant increase of 39.51% compared to ¥2,972,163.26 in 2021[65]. - The number of R&D personnel increased by 27.27% from 11 to 14, with a notable rise in the number of staff under 30 years old[67]. - The company is currently developing several new products, including a portable fetal heart monitoring device and an AI-based cardiac ultrasound diagnostic system[66]. - The company is increasing R&D investment in modern traditional Chinese medicine to expand product variety and production capacity, while promoting the construction of the Luyan Bozhou Traditional Chinese Medicine Industrial Park[93]. Operational Efficiency - The gross profit margin for pharmaceutical products was 6.95%, showing a slight decrease of 0.11% compared to the previous year[56]. - The total operating costs amounted to ¥16,926,820,791.07, which is 94.31% of total operating costs, up by 10.41% from the previous year[58]. - The company reported a 30% increase in operational efficiency due to new technologies implemented in the production process[175]. - The company aims to reduce operational costs by 5% through strategic initiatives in the next fiscal year[175]. Governance and Compliance - The governance structure of the company complies with relevant laws and regulations, with regular meetings held to ensure effective management and risk control[97]. - The company has established a financial control mechanism to guide business management and optimize investment models, focusing on risk control in mergers and acquisitions[91]. - The company emphasizes the importance of internal control and risk prevention mechanisms to adapt to market policy changes and enhance compliance management[91]. - The company has not reported any penalties from securities regulatory agencies for its directors and supervisors in the past three years[116]. Shareholder Engagement - The company plans to implement a three-year shareholder return plan from 2022 to 2024[102]. - A cash dividend of 3.00 CNY per 10 shares (including tax) was approved, with a total cash dividend amounting to 116,555,020.80 CNY, representing 100% of the profit distribution[130]. - The company held a temporary shareholders' meeting on January 10, 2022, with a participation rate of 39.86%[102]. - The annual shareholders' meeting on May 17, 2022, also had a participation rate of 39.82%[102]. Social Responsibility - The company has maintained a focus on social responsibility, particularly in healthcare support during the pandemic[143]. - The company processed and delivered nearly 7 million bags of traditional Chinese medicine during the pandemic, supporting local governments and healthcare institutions[37]. - The company distributed 100,000 tablets of ibuprofen for free through its pharmacies to address public demand during shortages[143]. Future Outlook - The company projects a revenue growth of 10% for the upcoming fiscal year, aiming for a target of approximately 4,761 million[175]. - Future guidance indicates a projected revenue growth of 10% for 2023, driven by new product launches and market expansion strategies[179]. - The company plans to expand its market presence with new product launches and technological advancements in 2023[184].

证券代码：002788 证券简称：鹭燕医药 公告编号：2023-013 鹭燕医药股份有限公司 关于举行 2022 年年度报告网上业绩说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 鹭燕医药股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日在巨潮资讯网 （http://www.cninfo.com.cn/）上披露了《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者进一步了解公司 2022 年年度经营情况，公司定于 2023 年 4 月 21 日 （星期五）下午 15：00-17：00 举行 2022 年年度报告网上业绩说明会。本次业绩说明会将 采用网络远程交流的方式举行，投资者可登陆"鹭燕医药投资者关系"小程序参与互动交流。 为广泛听取投资者的意见和建议，提前向投资者征集问题，提问通道自发出公告之日起开放。 参与方式一：在微信中搜索"鹭燕医药投资者关系"小程序； 参与方式二：微信扫一扫以下二维码： 2023 年 4 月 18 日 投资者依据提示，授权登入"鹭燕医药投资者关系"微信小程序，即可参与交流。 出席 ...